Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

Presentation TCT 2025

Treatment Adherence and Adverse Events After Combined TAVR and LAAC or TAVR and Oral Anticoagulation in Patients with Atrial Fibrillation: The WATCH-TAVR OAC Compliance Study

Presenter: Grant William Reed

October 25, 2025

Presentation NY Valves 2025

LAAC in the Presence of Thrombus: When OAC Fails

Presenter: Brian P. O'Neill

June 26, 2025

Presentation NY Valves 2025

Outcomes in Patients Discharged on OAC vs. DAPT After Left Atrial Appendage Occlusion Using a Fluoropolymer Coated Device: A Sub-analysis of the HEAL-LAA Post Approval Study

Presenter: Seun Alli

June 25, 2025

Presentation TVT 2023

The Case for ‘Default OAC’ in Valve-in-Valve TAVR – Pros and Cons

Presenter: Isaac George

June 08, 2023

Presentation

Switching of OAC After PCI in A-fib Patients:RE-DUAL PCI Trial Subanalysis

December 04, 2019

Presentation TCT 2019

Approaches to Reduce Bleeding Risk Post PCI in Patients Requiring OAC: Is There Any Role for ASA?

Presenter: C. Michael Gibson

September 28, 2019

Presentation TCT 2019

When and How to Switch to OAC Alone After PCI?

Presenter: Manesh Patel

September 27, 2019

Presentation TCT 2019

PCI in Patients Requiring OAC: Which OAC and in Whom?

Presenter: Davide Capodanno

September 27, 2019

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presentation TCT 2019

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presenter: C. Michael Gibson

September 27, 2019

Presentation TCT 2018

OAC ALONE: Summary and Clinical Implications

Presenter: John A. Bittl, David Erlinge, Takashi Kubo, Yukiko Nakano

September 24, 2018

Presentation TCT 2018

A Patient With DVT, Pulmonary Embolus and PFO: Close on OAC?

Presenter: Zahid Amin, Robert J. Sommer, Peter C. Block, John P. Breinholt, Craig E Fleishman, Jan Kovac, Harsimran Sachdeva Singh, Christian Spies

September 24, 2018

Presentation TCT 2018

A Patient With Atrial Fibrillation, Cryptogenic Stroke, and PFO: Watchman Despite OAC?

Presenter: Zahid Amin, Robert J. Sommer, Peter C. Block, John P. Breinholt, Craig E Fleishman, Jan Kovac, Harsimran Sachdeva Singh, Christian Spies

September 24, 2018

Presentation TCT 2018

OAC-ALONE: A Randomized Trial of Oral Anticoagulation With vs Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation Beyond One Year After Coronary Stent Implantation

Presenter: Gregg W. Stone, Yukiko Nakano

September 24, 2018

Presentation TCT 2018

Featured Lecture: The High-risk Patient: Risk Assessment and Current Recommendations for DAPT and OAC

Presenter: Bagrat Alekyan, Juan F. Granada, Roxana Mehran

September 22, 2018

Presentation TCT 2017

Should the Type of Stent Influence DAPT Decisions in Patients Receiving OAC? Insights From WOEST, LEADERS Free, and More

Presenter: Robert A. Harrington, Kurt Huber, Didier Carrié

November 01, 2017

Presentation TCT 2016

TCT 54: LEADERS FREE OAC: Biolimus A9 Coated vs Bare Metal Stents in Patients Requiring Oral Anticoagulation. A Prespecified Subgroup Analysis of the LEADERS FREE Trial

Presenter: Neal S. Kleiman, David F. Kong, Didier Carrié

October 31, 2016

Presentation

Oral Anticoagulation (OAC) and Antiplatelets inA-fib Patients After MI and PCI

Presenter: M. Lamberts

June 12, 2013

Presentation ESC 2012

WOEST: First randomised trial that compares two different regimens with and without aspirin in patients on oral anticoagulant therapy (OAC) undergoing coronary stent placement (PCI)

Presenter: Willem Dewilde

August 28, 2012

Advertisement

Treatment Adherence and Adverse Events After Combined TAVR and LAAC or TAVR and Oral Anticoagulation in Patients with Atrial Fibrillation: The WATCH-TAVR OAC Compliance Study

LAAC in the Presence of Thrombus: When OAC Fails

Outcomes in Patients Discharged on OAC vs. DAPT After Left Atrial Appendage Occlusion Using a Fluoropolymer Coated Device: A Sub-analysis of the HEAL-LAA Post Approval Study

The Case for ‘Default OAC’ in Valve-in-Valve TAVR – Pros and Cons

Switching of OAC After PCI in A-fib Patients:RE-DUAL PCI Trial Subanalysis

Approaches to Reduce Bleeding Risk Post PCI in Patients Requiring OAC: Is There Any Role for ASA?

When and How to Switch to OAC Alone After PCI?

PCI in Patients Requiring OAC: Which OAC and in Whom?

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

OAC ALONE: Summary and Clinical Implications

A Patient With DVT, Pulmonary Embolus and PFO: Close on OAC?

A Patient With Atrial Fibrillation, Cryptogenic Stroke, and PFO: Watchman Despite OAC?

OAC-ALONE: A Randomized Trial of Oral Anticoagulation With vs Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation Beyond One Year After Coronary Stent Implantation

Featured Lecture: The High-risk Patient: Risk Assessment and Current Recommendations for DAPT and OAC

Should the Type of Stent Influence DAPT Decisions in Patients Receiving OAC? Insights From WOEST, LEADERS Free, and More

TCT 54: LEADERS FREE OAC: Biolimus A9 Coated vs Bare Metal Stents in Patients Requiring Oral Anticoagulation. A Prespecified Subgroup Analysis of the LEADERS FREE Trial

Oral Anticoagulation (OAC) and Antiplatelets inA-fib Patients After MI and PCI

WOEST: First randomised trial that compares two different regimens with and without aspirin in patients on oral anticoagulant therapy (OAC) undergoing coronary stent placement (PCI)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content